Aberdeen Group plc decreased its stake in Axon Enterprise, Inc (NASDAQ:AXON – Free Report) by 6.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 92,278 shares of the biotechnology company’s stock after selling 6,380 shares during the period. Aberdeen Group plc owned approximately 0.12% of Axon Enterprise worth $66,121,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. grew its position in Axon Enterprise by 3.5% in the 2nd quarter. Vanguard Group Inc. now owns 8,937,260 shares of the biotechnology company’s stock worth $7,399,515,000 after purchasing an additional 305,252 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Axon Enterprise by 5.9% in the second quarter. Geode Capital Management LLC now owns 2,072,186 shares of the biotechnology company’s stock valued at $1,713,332,000 after buying an additional 115,349 shares during the period. Jennison Associates LLC lifted its stake in shares of Axon Enterprise by 53.8% in the third quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company’s stock valued at $677,412,000 after buying an additional 330,213 shares during the period. Vestor Capital LLC grew its position in Axon Enterprise by 438,636.3% during the second quarter. Vestor Capital LLC now owns 833,599 shares of the biotechnology company’s stock worth $690,170,000 after buying an additional 833,409 shares in the last quarter. Finally, Norges Bank bought a new position in Axon Enterprise during the second quarter valued at about $637,806,000. Institutional investors own 79.08% of the company’s stock.
Axon Enterprise Stock Down 1.4%
Shares of NASDAQ:AXON opened at $429.67 on Monday. The company’s fifty day moving average is $557.56 and its 200-day moving average is $647.45. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.89 and a current ratio of 3.12. Axon Enterprise, Inc has a 52 week low of $396.41 and a 52 week high of $885.91. The company has a market capitalization of $33.91 billion, a PE ratio of 135.97, a P/E/G ratio of 12.94 and a beta of 1.48.
Insider Transactions at Axon Enterprise
Analysts Set New Price Targets
AXON has been the subject of several recent research reports. TD Cowen reaffirmed a “buy” rating on shares of Axon Enterprise in a report on Wednesday, November 5th. Barclays cut their target price on Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a research note on Thursday, November 6th. UBS Group decreased their price target on shares of Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Piper Sandler dropped their price objective on shares of Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Finally, Royal Bank Of Canada initiated coverage on shares of Axon Enterprise in a report on Monday, November 17th. They set an “outperform” rating and a $860.00 price objective for the company. Fifteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Axon Enterprise has an average rating of “Moderate Buy” and a consensus price target of $805.71.
View Our Latest Report on AXON
Axon Enterprise Profile
Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.
Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.
Read More
- Five stocks we like better than Axon Enterprise
- This $15 Stock Could Go Down as the #1 Stock of 2026
- I’m 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (Ask An Advisor)
- America’s 1776 happening again
- Trump & Musk’s Secret Bet on Silver — Exposed
- Your Bank Account Is No Longer Safe
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.
